Bayer to buy Roche
This article was originally published in The Rose Sheet
Executive SummaryBayer's proposed acquisition of Roche Consumer Health will create third largest OTC marketer worldwide, boosting Bayer HealthCare from its sixth-place spot to a position trailing only Johnson & Johnson and GlaxoSmithKline. Bayer/Roche combination is expected to have annual worldwide sales of $2.99 bil. Bayer's commitment to grow its consumer health business is reflected in the $2.96 bil. price tag it agreed to pay for Roche, representing twice the unit's annual sales. Under the deal, Bayer will acquire Roche's 50% share of the joint marketing venture for Aleve, which the firms have shared, as well as a number of other analgesic, dermatological, gastrointestinal and nutritional brands that will complement its own portfolio. Roche's leading consumer brands include Supradyn multivitamins, topical ointment Bepanthen, antacid Rennie and vitamin C supplement Redoxon. Company also manufactures Parsol UV filters...
You may also be interested in...
The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.